Arbutus Biopharma (ABUS) – Major News
-
Arbutus Biopharma (ABUS) Misses Q3 EPS by 1c
-
Arbutus Biopharma (ABUS) Tops Q2 EPS by 1c
-
Arbutus Biopharma (ABUS) Misses Q4 EPS by 33c
-
Arbutus Biopharma (ABUS) Tops Q3 EPS by 2c
-
Arbutus Biopharma (ABUS) Tops Q3 EPS by 2c
-
Arbutus Biopharma (ABUS) Tops Q2 EPS by 2c
-
Arbutus Biopharma (ABUS) Tops Q1 EPS by 5c
-
Arbutus Biopharma (ABUS) Reports In-Line Q3 EPS; Cash and Cash Equivalents of 151.9M
-
Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c
-
Arbutus Biopharma (ABUS) Tops Q1 EPS by 2c
-
Arbutus Biopharma (ABUS) Misses Q3 EPS by 5c
-
Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c
-
Arbutus Biopharma (ABUS) Tops Q1 EPS by 14c
-
Arbutus Biopharma (ABUS) Misses Q3 EPS by $1.11
-
Arbutus Biopharma (ABUS) Misses Q2 EPS by 7c
-
Arbutus Biopharma (ABUS) Misses Q1 EPS by 8c
-
Arbutus Biopharma (ABUS) Reports FY18 Loss of $1.21
-
Arbutus Biopharma (ABUS) Misses Q3 EPS by 10c
-
Arbutus Biopharma (ABUS) Misses Q2 EPS by 5c
-
Arbutus Biopharma (ABUS) Reports Q1 Loss of $0.36/Share
-
Arbutus Biopharma (ABUS) Tops Q3 EPS by 20c
-
Arbutus Biopharma (ABUS) Tops Q2 EPS by 9c
-
Arbutus Biopharma (ABUS) Tops Q1 EPS by 10c, Beat on Revenues
-
Arbutus Biopharma (ABUS) Licenses LNP Delivery Technology to Alexion (ALXN); Agreement Includes $7.5M Upfront
-
Arbutus Biopharma (ABUS) Reports New Results from Ongoing Phase II Study of ARB-1467 in HBV Patients
-
Arbutus Biopharma (ABUS) Announces Results from Phase II Trial of ARB-1467 for Chronic HBV Infection
Back to ABUS Stock Lookup
